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Sex Med 2Introduction: The prevalence of menopausal women with conﬁrmed vulvovaginal atrophy (VVA) oscillates
between 67e98%.
Aim: To assess the prevalence of postmenopausal women with VVA conﬁrmed by gynecologic clinical assess-
ment among all women attending menopause centers in Spain, as well as to describe the impact of VVA on
quality of life and sexual functioning.
Methods: Women aged 45e75 years old with the last menstrual period >12 months before were included in a
cross-sectional study.
Main Outcome Measures: Women with 1 VVA symptoms ﬁlled out a number of questionnaires, including
EuroQoL, Day-to-Day Impact of Vaginal Aging, Female Sexual Function Index, and Female Sexual Distress
Scale-revised. A gynecologic examination was performed to conﬁrm diagnosis.
Results: 1,177 evaluable patients were included. VVA was conﬁrmed in 87.3% of the patients. Almost 80% of
women who acknowledged being sexually active (n ¼ 717) presented pain during intercourse. As compared with
patients without conﬁrmed VVA (n¼ 66), patients with conﬁrmed VVA (n¼ 1,028) were signiﬁcantly older (P<
.0001), had lower rates of sexual activity (P< .05), and used more VVA treatments (P< .05). Severe vaginal atrophy
and severe vulvar atrophy were more prevalent in VVA-conﬁrmed women (P< .0001, in both cases). No differences
regarding the conﬁrmation of VVAwere observed for EuroQoL andDay-to-Day Impact of Vaginal Aging quality-of-
life questionnaires. Sexual function measured through the Female Sexual Function Index score was signiﬁcantly
reduced in sexually-active patients with conﬁrmed VVA (P < .05).
Conclusion: VVA signs and symptoms are highly prevalent in Spanish postmenopausal women. Conﬁrmation of
VVA diagnosis was associated with impaired sexual function. The early recognition of VVA symptoms should be
actively promoted in medical practice, instead of waiting until signs appear to exclude other reasons for VVA and
to manage treatment effectively. Palacios S, González SP, Fernández-Abellán M, et al. Impact of Vulvova-
ginal Atrophy of Menopause in Spanish Women: Prevalence and Symptoms According to the EVES Study.
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Vulvovaginal atrophy (VVA) is a relatively common condition
after menopause. The reduction in plasma levels of estrogen leads
to physiological, histologic, and anatomic changes in the lower
genital and urinary tracts, which are rich in estrogen receptors.
Estrogen levels play a signiﬁcant role in maintaining thickness
and urogenital territory moisture through the safeguarding of the
mucopolysaccharide and collagen content of the mucosa.1 The
main consequence of a hypoestrogenic environment is thinning
of the vaginal epithelium and alteration to squamous and strat-
iﬁed tissue that promotes loss of elasticity and blood ﬂow.
Additionally, vaginal pH increases >5 due to changes in vaginal
ﬂora.2 The associated group of VVA symptoms after post-
menopausal estrogen deﬁciency were recently grouped together
as genitourinary syndrome of menopause,3 are grouped under
genital, sexual, and urinary origin,4 and include loss of vaginal
elasticity, dryness, decreased lubrication, irritation, and dyspar-
eunia, among others. Notwithstanding the impact of VVA on an
aging population in Spain and Europe,5 in many cases, meno-
pausal women considered their symptoms as the normal outcome
of age, and so its clinical diagnosis is underreported, and its
treatment status remains unnoticed.6
The prevalence of menopausal women with symptoms of
VVA has been reported to be about 50%,7,8 whereas the per-
centage of these patients with VVA conﬁrmed by examination
oscillates between 67e98%.9 Clinical symptoms of VVA are
linked with major psychosocial distress10 and underreporting
that leads to chronicity, disease progression, and a considerable
impact on women’s daily living,6,11 despite the currently avail-
able therapeutic options. Treatment for VVA includes local
moisturizers, lubricants, and local estrogens, as well as systemic
estrogen therapy when other postmenopausal symptoms were
observed. In recent years (January 2015), the selective estrogen
receptor modulator ospemifene has also been approved by the
European Medicines Agency for the treatment of moderate to
severe symptomatic VVA in postmenopausal women who are not
candidates for treatment with local vaginal estrogens.
The objective of the present analysis of the European Vulvo-
vaginal Epidemiology Survey (EVES)12 was to assess the preva-
lence of postmenopausal women with VVA conﬁrmed by
gynecologic clinical assessment among all postmenopausal
women attending menopause centers in Spain. Additionally,
other aims of the analyses included assessing the characterization
of the VVA Spanish population (including lifestyle, reproductive
history, sexual behavior, chronic diseases, treatment), as well as
the assessment of the overall impact of VVA on quality of life and
sexual functioning in Spain. Surveys on this issue in Europe and
Spain have usually been performed following online-based
questionnaires.11,13,14 However, this analysis is based on a new
study performed with a face-to-face survey, together with the
conﬁrmatory gynecologic examination, and has a different and
innovative value for the characterization of this population of
postmenopausal women in Spain.MATERIAL AND METHODS
Design and Patients
A cross-sectional study, based on a face-to-face survey
addressed to postmenopausal women, was performed in 44
menopausal and gynecologic clinics from Italy and Spain.12 The
study was approved by the Institutional Review Board of the
participant sites and conducted in accordance with the Decla-
ration of Helsinki. Written informed consent was provided by all
patients before study entry. This analysis was focused on post-
menopausal women (>12 months after the last reported men-
strual period), aged 45e75 years old, and included in the 4
menopause and 17 Spanish gynecology centers.Study Procedures
Women were asked to participate in the survey when attending
menopause/gynecologic clinics. Initially, investigators performed a
menopausal status assessment (including a medical history to
identify contributing factors, alternative causes, and therapeutic
interventions) and a pelvic examination speciﬁcally to identify
signs consistent with VVA (Survey Part A), following guidelines
evidence15). For women who did not report any VVA symptoms,
no additional data were collected. On the other side, women
reporting 1 VVA symptoms completed parts B and C of the
survey. Part B asked for demographic details, lifestyle, medical
history, and treatment information. In addition, women scored 19
VVA-related complaints about vaginal, vulvar, and urinary
symptoms using a 4-score severity scale (absent, mild, moderate,
and severe). For each type of symptoms (vaginal, vulvar, and uri-
nary), we obtained a score of severity. Part C of the survey consisted
of questions measuring the impact of VVA on quality of life and
sexual function. The EuroQoL (EQ) questionnaire (EQ5D3L)16
obtains a score measuring mobility, self-care, activities of daily
living, pain-discomfort, and anxiety-depression; it also includes a
visual analog scale for current health status. The EQ5D3L health
states may be converted into a single summary utility index,
ranging from 0e1, by applying a prespeciﬁed formula that
essentially attaches values (weights) to each of the levels in each
dimension. The Day-to-Day Impact of Vaginal Aging (DIVA)17
questionnaire scores 4 dimensions measuring quality of life
(daily activities, emotional well-being, sexual functioning, and self-
concept and body image). The self-concept and body image di-
mensions are related to those items that may affect feelings about
oneself and body conception.17 The patients also ﬁlled out
the Female Sexual Function Index (FSFI),18 which measures
sexual activity, and the Female Sexual Distress Scale-revised 2005
(FSDS-R), which depicts sexual concerns and distress.19
A ﬁnal gynecologic clinical assessment for the presence of VVA
was performed by investigators (1 per center; all investigators
followed the same guideline parameters to perform the gyneco-
logic examination15) consisting of a physical examination, with
additional tests (including the pelvic examination and a vaginal
pH assessment) carried out in accordance with routine gyneco-
logic clinical practice (Part D). The investigators ﬁlled out allSex Med 2019;7:207e216
Patients evaluable 
for VVA symptoms
(n=1177)
No VVA symptoms (n=21)
Patients enrolled 
(n=1182)
Not screened for VVA symptoms (n=5)
They did not fill out Questionnaire-part A
Vulvovaginal Atrophy in Spanish Women 209signs of VVA to calculate the Vaginal Health Index20 and the
Vulva Health Index .13 Vaginal Health Index scores overall
elasticity, ﬂuid secretion, vaginal pH, aspect of epithelial mucosa
and moisture all together between 5e25, with lower scores
corresponding to more urogenital atrophy (total score <15
corresponds to vaginal atrophy). The Vulva Health Index scores
the aspect of labia, urethra, clitoris, and introitus, as well as
elasticity, petechiae, and pain during intercourse all together
between 0e24, with higher scores corresponding with greater
vulvar atrophy. Vulvar atrophy is suggested with a Vulva Health
Index >8 or if there is a score of 3 (severe) in any category.Patients evaluable for 
Questionnaires
(n=1094)
Patients with 
assessment of VVA
(n=1094)
VVA assessment missing (n=0)
Patients with VVA 
confirmed by HCP 
(n=1028)
VVA not-confirmed (n=66)
Patients with at least 
ONE VVA symptom 
(n=1156)
Not screened for Questionnaires (n=62).
They did not fill out Questionnaire-part BCD
Figure 1. Study ﬂow-chart of Spanish participants.Statistical Analyses
Approximately 1,000 Spanish patients were planned for
completion of the face-to-face survey to obtain a sufﬁciently
representative sample size of the postmenopausal women with
VVA symptoms in Spain. The output of the sample size calcu-
lation was based on random sampling from an inﬁnite popula-
tion and on the assumption of normal approximation (P ¼ .500,
D ¼ 0.030, a ¼ 0.05). Speciﬁcally, we applied a sample size
calculation based on population proportion estimation. We
considered the proportion among all postmenopausal women
attending menopause Spanish centers with a VVA conﬁrmed by
gynecologic clinical assessment in approximately 0.50. A 95% CI
was desired, with precision D ¼ 0.030. Thus, a sample size of
1,068 participants was considered. Taking into consideration
that the population referring 1 VVA symptom could represent
40e60% of the population attending the menopause centers,
and that 10% of questionnaires were not expected to be
adequately ﬁlled in, a total population of 1,167 subjects was
initially considered to be recruited.
For continuous variables, descriptive statistics include means,
range, SD, and range for normally distributed variables, as well as
medians and interquartile range. No missing data were imputed.
Categorical variables were summarized as counts and percent-
ages. The relationship between conﬁrmed diagnosis of VVA and
demographic characteristics was performed with c2 testing.
Student’s t-test was used to compare quantitative variables.RESULTS
From a total of 2,412 postmenopausal women initially
enrolled in the European EVES study (from Italy and Spain),
1,182 (49%) women were recruited in Spanish outpatient
menopause (n ¼ 357; 30%) or gynecology centers (n ¼ 825;
70%). Among them, 1,177 women were included and evaluable
for screening of symptoms (part A), whereas 1,094 women
complained of 1 symptom related to VVA, ﬁlled out the
questionnaires, and had an objective gynecologic examination
(evaluable for parts B,C,D) (see ﬂowchart in Figure 1).
Mean age ± SD of the included patients was 58.9 ± 6.2 years,
and they had been in menopause for 10.1 ± 6.8 years. Among
these 1,094 women, 958 (87.6%) experienced physiologicalSex Med 2019;7:207e216menopause, 99 (9.0%) had surgically induced menopause, and
37 (3.4%) had menopause promoted by medication. De-
mographic characteristics of the patients in subpopulations are
listed in Table 1, with statistically signiﬁcant differences detected
in age, time since onset of menopause, type of menopause, and
relationship status between women with VVA conﬁrmed and
those not conﬁrmed under gynecologic assessment. No signiﬁ-
cant differences between included (n ¼ 1,094) and not included
women (n ¼ 88) were observed for age, age at last menstruation,
time since onset of menopause, and type of menopause. The
most frequent events in the gynecologic history of the included
population involved abortion/miscarriage (25.3%), hysterectomy
(14.9%), and breast disease (9.7%). In addition, chronic diseases
were observed in 69.0% of the patients (see Table 1 for details),
with hypertension and hypercholesterolemia being the most
globally reported chronic diseases for the whole sample. This was
conﬁrmed for women with an objective VVA that showed the
highest prevalence in these 2 comorbid diseases (20.7% and
18.5%, respectively). In the case of non-conﬁrmed VVA, the
most prevalent chronic disease was anxiety (16.7%), followed by
hypercholesterolemia (13.6%). Anxiety was signiﬁcantly more
Table 1. Baseline characteristics of the patients
With 1 VVA
symptom and VVA
assessment (n ¼ 1,094)
With 1 VVA symptom and VVA
assessment (N ¼ 1,094)
P*
No VVA conﬁrmed
(n ¼ 66)
VVA conﬁrmed
(N ¼ 1,028)
Age (y), mean ± SD [Range] 58.9 ± 6.2 [45e76] 53.5 ± 5.6 [45e75] 59.2 ± 6.1 [45e76] .000
Age at last menstruation (y),
mean ± SD [Range]
48.8 ± 4.9 [10e65] 48.3 ± 4.0 [34e55] 48.9 ± 4.9 [10e65] .499
Time since menopause (y),
mean ± SD [range]
10.1 ± 6.8 [1e48] 5.2 ± 5.1 [1e28] 10.4 ± 6.8 [1e48] .000
Type of menopause, n (%) .000
Natural 958 (87.6) 49 (74.2) 909 (88.4)
Induced by medications 37 (3.4) 10 (15.2) 27 (2.6)
Surgical 99 (9.0) 7 (10.6) 92 (8.9)
BMI, mean ± SD [Range] 26.0 ± 4.5
[15.3e49.3]
25.9 ± 4.5
[17.7e42.2]
26.0 ± 4.5
[15.3e49.3]
.798
Relationship status, n (%) .040
Married 800 (73.1) 43 (66.2) 757 (77.2)
Single 98 (9.0) 10 (15.4) 88 (9.0)
Widowed 59 (5.4) 2 (3.1) 57 (5.8)
In a relationship 89 (8.1) 10 (15.4) 79 (8.1)
Education, n (%) .155
Elementary 361 (33.5) 27 (41.5) 334 (33.0)
High school 374 (34.2) 24 (36.9) 350 (34.6)
Graduate 343 (31.4) 14 (21.5) 329 (32.5)
Employment status (Yes), n (%) 616 (56.1) 43 (65.2) 573 (56.6) .132
Tobacco use (Yes), n (%) 235 (21.5) 27 (40.9) 208 (20.3) .000
Treatments, n (%) .023
None 536 (49.0) 41 (62.1) 497 (48.3)
At least 1 treatment used 572 (52.3) 25 (37.9) 547 (53.2)
No. of treatments used
1 441 (40.3) 20 (30.3) 421 (41.0)
2 121 (11.1) 4 (6.1) 117 (11.4)
3 10 (0.9) 1 (1.5) 9 (0.9)
Non-hormonal therapy applied
vaginally, n (%)
464 (42.4) 22 (33.3) 442 (43.0) .157
Hormonal (estrogen-containing)
vaginally, n (%)
178 (16.3) 4 (6.1) 174 (16.9) .016
Hormonal (estrogen-containing)
systemic, n (%)
48 (4.4) 4 (6.1) 44 (4.2) .712
Effectiveness, n (%) .564
No relief 26 (5.3) 1 (5.3) 25 (5.3)
Low relief 131 (26.5) 3 (15.8) 128 (26.9)
Moderate relief 139 (28.1) 6 (31.6) 133 (28.0)
Good relief 145 (29.4) 5 (26.3) 140 (29.5)
High relief 53 (10.7) 4 (21.1) 49 (10.3)
Treatment period, n (%) .042
1 week 27 (5.5) 0 (0.0) 27 (5.7)
1e4 weeks 53 (10.8) 6 (33.3) 47 (10.0)
1e3 months 62 (12.7) 0 (0.0) 62 (13.2)
3e6 months 62 (12.7) 2 (11.1) 60 (12.7)
>6 months 285 (58.3) 10 (55.6) 275 (58.4)
(continued)
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Table 1. Continued
With 1 VVA
symptom and VVA
assessment (n ¼ 1,094)
With 1 VVA symptom and VVA
assessment (N ¼ 1,094)
P*
No VVA conﬁrmed
(n ¼ 66)
VVA conﬁrmed
(N ¼ 1,028)
Overall satisfaction with the
treatment, n (%)
.498
Very low satisfaction 30 (6.0) 1 (5.9) 29 (6.0)
Low satisfaction 99 (19.9) 1 (5.9) 98 (20.4)
Moderate satisfaction 184 (36.9) 6 (35.3) 178 (37.0)
High satisfaction 138 (27.7) 6 (35.3) 132 (27.4)
Very high satisfaction 47 (9.4) 3 (17.6) 44 (9.1)
Reason for not being satisﬁed, n (%) .224
Not effective enough 121 (45.1) 4 (50.0) 117 (45.0)
Worried about side effects 31 (11.6) 3 (37.5) 28 (10.8)
Too expensive 18 (6.7) 0 (0.0) 18 (6.9)
Difﬁcult or unable to apply vaginally 14 (5.2) 0 (0.0) 14 (5.4)
Messiness of treatment 56 (20.9) 1 (12.5) 55 (21.2)
Other 28 (10.4) 0 (0.0) 28 (10.8)
Currently sexually active (Yes), n (%) 717 (66.3) 47 (71.2) 670 (66.0) .017
Intercourse (No./mo), mean ± SD [Range] 4.2 ± 3.4 [0-30] 5.7 ± 3.7 [0-16] 4.1 ± 3.3 [0-30] .000
Caucasian ethnic group, n (%) 921 (89.7) 62 (93.9) 859 (89.4) .023
Childbirth (Yes), n (%) 899 (82.9) 61 (92.4) 838 (82.3) .029
Abortion/miscarriage, n (%) 267 (25.3) 21 (32.8) 246 (24.8) .154
Chronic diseases (Yes), n (%)† 755 (69.0) 39 (59.1) 716 (69.6) .072
Hypertension 219 (20.0) 6 (9.1) 213 (20.7) .069
Hypercholesterolemia 199 (18.2) 9 (13.6) 190 (18.5) .712
Hypothyroidism 133 (12.2) 4 (6.1) 129 (12.5) .282
Osteoporosis 126 (11.5) 4 (6.1) 122 (11.9) .377
Anxiety 112 (10.2) 11 (16.7) 101 (9.8) .033
Arthrosis 109 (10.0) 6 (9.1) 103 (10.0) .816
Surgery for prolapse/urinary incontinence, n (%) 46 (4.3) 1 (1.5) 45 (4.5) .253
Breast disease (Yes), n (%) 105 (9.7) 11 (16.7) 94 (9.3) .052
If yes, Benign‡ 18 (17.1) 1 (9.1) 17 (18.1)
If yes, Malignant‡ 76 (72.4) 10 (90.9) 66 (70.2)
Hysterectomy, n (%) 161 (14.7) 7 (10.6) 154 (15.2) .355
BMI ¼ body mass index; VVA ¼ vulvovaginal atrophy.
Totals and percentages calculated among the total number of available responses for each variable.
*No-VVA vs VVA conﬁrmed comparisons.
†Diseases with 10% or more are shown. Fisher exact test calculated for each chronic disorder among the total patients with chronic disorders (n¼ 39 and n ¼
716).
‡Percentages calculated among the total of patients with breast disease.
Vulvovaginal Atrophy in Spanish Women 211prevalent in the VVA-conﬁrmed group compared with women
without a conﬁrmed VVA diagnosis (P ¼ .033).
Regarding the primary objective, the prevalence of post-
menopausal women with VVA conﬁrmed by gynecologic clinical
assessment among all postmenopausal women attending meno-
pause centers in Spain was 87.3% (1,028 of 1,177). In relation
to secondary objectives, the prevalence of women with 1
symptom possibly related to VVA was 98.2% (1,156 of 1,177
enrolled women), for whom the mean number of symptoms was
5.4 ± 2.6 (range 1e14) and the most common symptom was
vaginal dryness (90.8%), followed by pain during intercourse
(72.2%) and burning (63.3%), as shown in Table 2. WithinSex Med 2019;7:207e216those women who acknowledged being sexually active
(n ¼ 717), 79.4% reported pain during the intercourse.
Women whose VVA was conﬁrmed by their physician
(n ¼ 1,028) were on average 5.7 years older than those
whose VVA was not conﬁrmed (n ¼ 66) (P < .0001).
Similarly, they presented an average of 5.2 years more (P <
.0001) after the onset of menopause. Patients with
conﬁrmed VVA also presented signiﬁcantly lower rates of
menopause induced by medications (P < .0001). VVA
conﬁrmation was also associated with tobacco use (P <
.0001), lower sexual activity (P < .05) and higher use of
VVA treatments (P < .05) (Table 1).
212 Palacios et alVulvovaginal discomfort was evaluated for all women pre-
senting 1 symptom and who had completely ﬁlled out ques-
tionnaires by using a rating scale for severity. Symptoms by main
category (vaginal, vulvar, urinary) and the resulting scores were
compared between women whose VVA was conﬁrmed or not by
their physician during gynecologic visit (Table 3). The score for
severity was signiﬁcantly higher in the VVA-conﬁrmed group as
compared with the VVA not conﬁrmed group for vaginal and
vulvar pooled symptoms, as well as for the total symptom score.
The mean Vaginal Health Index was signiﬁcantly lower in
Spanish women whose VVA was conﬁrmed by their physician
(12.1 ± 3.4 vs 17.9 ± 2.4, respectively; P < .0001), and, overall,
vaginal atrophy as deﬁned by a Vaginal Health Index <15 was
more prevalent in VVA-conﬁrmed women (78.4% vs 6.1%, P <
.0001). The mean Vulva Health Index was higher in women
whose VVA was conﬁrmed by their physician (10.3 ± 4.5 vs 4.1
± 2.2, P < .0001), and, overall, severe vulvar atrophy (Vulva
Health Index >8 or a score of 3/”severe” in any category) was
highly prevalent in women with conﬁrmed VVA (67.0%) in
comparison with women with no VVA, in whom it was
conﬁrmed to be absent (P < .0001).
Conﬁrmation of VVA by the physician after vaginal exami-
nation is associated with a trend to lower current health state
than when no VVA is conﬁrmed, as shown by the scores
resulting from the EQ5D3L and EQevisual analog scale
(Table 3), although no statistical signiﬁcance was reached.
Among the 5 domains of problems in the EQ5D3L question-
naire, no signiﬁcant differences were observed depending on the
conﬁrmation of VVA. In case of the DIVA, where a higher score
means greater impact of vaginal symptoms, women whose VVA
was conﬁrmed by their physician had statistically no differences
in their score compared with those in whom VVA was not
conﬁrmed, except for the “self-concept and body image”
dimension (P < .05).Table 2. Prevalence of symptoms referred by the patients
With 1 VVA symptom
and VVA assessment
(n ¼ 1,094)
Wit
No-
Vaginal dryness 90.8% 75.
Pain during intercourse 72.2% 59.1
Pain during exercise 20.4% 1.
Bleeding during/after intercourse 17.5% 3.
Burning or irritation 63.3% 43.
Itching 59.9% 39.4
Vaginal Discharge 26.0% 13.
Urinary incontinence 34.3% 31.
Urinary urgency 36.2% 31.
Urinary frequency 46.5% 24.
Dysuria 14.4% 19.7
Recurrent urinary tract infections 18.8% 16.7
Postcoital cystitis 15.2% 4.
Abdominal pain 24.2% 22.7
VVA ¼ vulvovaginal atrophy.Compared with those patients with VVA not conﬁrmed, the
difference in the sexual function was signiﬁcantly different be-
tween sexually active patients (n¼ 717)withVVA conﬁrmed vs no
VVA conﬁrmed for the overall FSFI score (20.1 ± 7.4 vs 23.3 ±
9.6; P< .05) and for the FSFI particular components of arousal (P
< .05), lubrication (P< .01), satisfaction (P< .05), and pain (P<
.0005) (see Figure 2). Signiﬁcant differences were also seen be-
tween Spanish, sexually active women with VVA conﬁrmed and
not conﬁrmed in the overall FSDS-R score (12.0 ± 12.7 vs 7.6 ±
10.3; P < .05) but not for the percentage of patients with severe
FSDS-R score (11) (41.9% vs 31.9%; P ¼ .202).DISCUSSION
The results of the current Spanish cohort analysis of the EVES
study show that the overall prevalence of VVA, conﬁrmed by gy-
necologic assessment in postmenopausal women from Spain who
visited a gynecology or menopause clinic for any reason, is high
(87%). This is in line with the prevalence detected by the recent
Atrophy of the vaGina in womAn in posT-menopause in itAly
(AGATA) study inwomenwith a similar sociodemographic proﬁle
from Italy, in which 64.7% of women at 1 year and 84.2% at 6
years after menopause had developed VVA.21 The condition af-
fects postmenopausal women in southern European countries and
demonstrates the need to adequately assess the effect of VVA
symptomatology on quality of life and sexual function through the
use of a well-established and veriﬁed set of instruments.
In Spain, postmenopausal women with VVA symptoms
experienced a median of >5 symptoms. Some of the more
recently published studies reported that the prevalence of
symptoms of VVA were between 40e63% in postmenopausal
women from Western countries,6,22e24 as well as in Asia.25 A
longitudinal study reported that 47% women who were at least 3
years postmenopausal reported vaginal dryness as compared withh 1 VVA symptom and VVA assessment (n ¼ 1,094)
PVVA conﬁrmed (n ¼ 66) VVA conﬁrmed n ¼ 1,028)
8% 91.7% .000
% 73.1% .014
5% 21.6% .000
0% 18.4% .001
9% 64.6% .001
% 61.2% .000
6% 26.8% .018
8% 34.4% .664
8% 36.5% .445
2% 48.0% .000
% 14.0% .201
% 19.0% .643
5% 15.9% .013
% 24.3% .770
Sex Med 2019;7:207e216
Table 3. Comparison of questionnaires between VVA conﬁrmed and VVA not conﬁrmed
With 1 VVA symptom
and VVA assessment
(N ¼ 1,094)
No-VVA conﬁrmed
(N ¼ 66)
VVA conﬁrmed
(N ¼ 1,028) P*
EuroQol-EQ5D3L, mean ± SD
(median)
0.875 ± 0.177 (0.914) 0.891 ± 0.173 (0.914) 0.874 ± 0.177 (0.914) .473
Health status (EQ VAS),
mean ± SD (median)
74.1 ± 16.2 (75) 76.4 ± 18.1 (80) 74.0 ± 10.0 (75) .254
DIVA total, mean ± SD (median) 0.902 ± 0.618 (0.842) 0.842 ± 0.613 (0.782) 0.906 ± 0.619 (0.849) .415
FSFI total, mean ± SD (median) 15.7 ± 9.8 (17.1) 19.4 ± 11.1 (22.6) 15.5 ± 9.6 (17.0) .001
FSDS-R total, mean ± SD (median) 11.2 ± 13.1 (6.0) 9.0 ± 11.4 (4.5) 11.4 ± 13.1 (6.0) .156
Female sexual dysfunction
(FSDS-R 11)
38.7% 36.4% 38.8% .692
Severity of symptoms†
Vaginal symptoms total score,
mean ± SD (median)
6.8 ± 4.4 (6) 4.6 ± 3.8 (4) 6.9 ± 4.4 (6) .000
Vulvar symptoms total score,
mean ± SD (median)
3.6 ± 2.6 (3) 2.6 ± 2.5 (2) 3.6 ± 2.6 (3) .003
Urinary symptoms total score,
mean ± SD (median)
2.9 ± 2.9 (2) 2.5 ± 2.8 (2) 2.9 ± 2.9 (2) .301
All symptoms total score, mean
± SD (median)
13.6 ± 8.1 (12) 10.1 ± 7.6 (8) 13.8 ± 8.1 (12) .000
DIVA ¼ Day-to-Day Impact of Vaginal Aging; EQ VAS ¼ visual analog scale; EQ5D3L ¼ EuroQoL; FSDS-R ¼ Female Sexual Distress Scale-revised; FSFI ¼
Female Sexual Function Index; VVA ¼ vulvovaginal atrophy.
*No-VVA vs VVA conﬁrmed comparisons.
†The VVA-related complaints were grouped in 3 main types of symptoms as follows: Vaginal symptoms included vaginal dryness (inside), pain during
intercourse (inside), pain during intercourse at penetration, bleeding during intercourse, bleeding during sexual contact, burning or irritation (inside), itching
(inside), and vaginal discharge.Vulvar symptoms included vaginal dryness (outside), burning or irritation (outside), itching (outside), and pain during exercise.
Urinary symptoms included urinary incontinence, urinary urgency, urinary frequency, urinary difﬁculties, recurrent urinary tract infections, and postcoital
cystitis. In addition abdominal pain was recorded as an independent symptom.
Vulvovaginal Atrophy in Spanish Women 2134% and 21% in early and late perimenopausal women, respec-
tively.26,27 Our Spanish results, in line with the overall EVES
study,12 show that the prevalence of VVA symptoms in post-
menopausal women visiting a gynecology/menopause clinic is
clearly higher than those numbers observed in population
cohorts and that vaginal dryness, pain during intercourse, and
burning may be extremely burdensome symptoms.
According to previous overall results,12 our data in Spain
support that an objective physical examination for gynecologic
VVA conﬁrmation under routine clinical practice is of preemi-
nent importance as shown by their signiﬁcant relationship with
sexual function and quality of life scores. >5% of Spanish
postmenopausal women with VVA symptoms had no VVA
conﬁrmed by a physician, either because VVA symptoms can be
experienced even before the observed evidence of VVA signs28 or
due to other causes. Thus, it has been reported the effects of
cognitive and emotional factors (ie, depression, anxiety)
contributing to the presence of early VVA symptomatology.29,30
Both a thorough history, as well as a gynecologic examination,
should clarify whether reasons other than postmenopausal VVA
are the cause of the symptoms that may require further investi-
gation and possibly different treatment options or whether early
symptoms of VVA should be treated to prevent further escalation
of symptoms and other complications.Sex Med 2019;7:207e216For the ﬁrst time, the VVA diagnosis conﬁrmation is evaluated
and performed as part of an observational VVA study in Spain
and has previously been included in another study conducted in
Italy.21 The AGATA study included 930 women and showed
that 79% of them had a diagnosis of VVA under objective
clinical examination. The AGATA study reported that signs and
symptoms of VVA do not show a strong correlation with each
other31 and that satisfaction with current treatments needs to be
improved.32 Overall, the Spanish branch of the EVES study
indicated that more than two-thirds of postmenopausal women
attending gynecology or menopause centers acknowledge the
presence of 1 chronic concurrent disease, highlighting hyper-
tension and hypercholesterolemia. When evaluating the presence
or absence of conﬁrmed VVA, anxiety seemed to be the most
prevalent chronic disease in women without a conﬁrmed diag-
nosis of VVA. This statement is in agreement with the fact that
some VVA symptoms appear even before the VVA objective
diagnosis has been done; anxiety or depression processes may
precede the existence of a conﬁrmatory objective VVA
diagnostic.29
Severity of VVA symptoms were also related with the conﬁr-
mation of VVA diagnosis, mainly for vaginal and vulvar symp-
toms, which scored higher severities when women were
diagnosed with VVA signs, demonstrating a delayed VVA
Radar chart presentation of No-VVA confirmed women (dark grey) compared to VVA confirmed 
women (light grey) for domains of the FSFI score in sexually active postmenopausal women. The 
values along the each axis of the radar chart are connected linearly to visualize the data set as a 
polygon. The perimeter of each polygon represents the mean value for each variable. 
* P<0.05; **P<0.005
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Figure 2. Domains of the FSFI score in the subpopulation of sexually active Spanish women. FSFI ¼ Female Sexual Function Index.
214 Palacios et alconﬁrmation in relation to symptom harshness. The results in
our Spanish cohort showed that an objective gynecologic diag-
nosis of VVA in postmenopausal women is linked with worse
vaginal health as measured by the mean Vaginal Health Index. In
a similar trend, our data showed that severe vulvar atrophy is
absent in women without VVA conﬁrmed but highly prevalent
when the VVA condition is certainly conﬁrmed.
In relation with the sexual function, the current Spanish results
evidenced that female sexual function measured by the FSFI was
signiﬁcantly inﬂuenced by the VVA diagnosis conﬁrmation,
mainly on components related to sexual arousal, lubrication,
orgasm, and pain. The vulvar and vaginal symptoms were already
acknowledged by women as factors affecting sexual activities in the
REVIVE (REal Women’s VIews of Treatment Options for
Menopausal Vaginal ChangEs) study.10,11,13 This trend may be
interpreted as a conﬁrmation of the Study of Women’s Health
Across the Nation that showed that women reporting vaginal
dryness were more likely to also report dyspareunia and lower
arousal sexual dysfunction.33 Additionally, it also supports theobservation that sexual dysfunction almost doubles with advanced
menopause status.34 In line with this, our data conﬁrm the idea
that sexual activities are affected by VVA symptoms, because we
found an inﬂuence of the objective VVA conﬁrmation over sexual-
related components (ie, sexual arousal or orgasm, among others).
Regarding the VVA impact on quality of life in Spanish
postmenopausal women, the questionnaires used in this study
allow the evaluation from 2 approaches: the general 1 (EQ5D3L)
and the 1 speciﬁc for vaginal aging (DIVA). No signiﬁcant link
of VVA diagnosis conﬁrmed by gynecologic examination with
quality of life was observed, whereas the evaluation of the speciﬁc
DIVA instrument showed a signiﬁcant worse “self-concept and
body image” dimension after the VVA objective diagnosis.
Probably, the global aspect of the EQ5D3L measure makes it
difﬁcult to ﬁnd a direct relationship between VVA diagnosis and
quality of life, because VVA probably affects the quality of life
components more as related to sexual life. Some reports have
already observed that women from Southern European countries
were more worried about the impact of vaginal discomfort onSex Med 2019;7:207e216
Vulvovaginal Atrophy in Spanish Women 215long-term effects of their relationship because it directly avoids
sexual intimacy.35
Some strengths and weaknesses need to be addressed before
we conclude this discussion. In comparison with most of the
surveys previously published that were performed in a tele-
phone or online environment, the current study combined a
face-to-face appointment for the completion of the question-
naires, with the objective physical examination that is a
cornerstone of the diagnosis of VVA. The face-to-face experi-
ence provide some advantages over other data collection
methods, such an increase in self-disclosure, the capture of
non-verbal aspects that may affect the quality of a response, as
well as the maintenance of the focus of participants’ atten-
tion.36 On the other hand, weaknesses include the lack of a
control group, the unbalanced sample sizes in some subgroup
comparisons, and the possible selection bias due to the fact that
many women with VVA do not seek medical help.CONCLUSIONS
In conclusion, both VVA signs and symptoms are highly
prevalent in Spanish postmenopausal women attending gyne-
cology/menopause clinics, although the objective VVA diagnosis
shows that 5% of women complaining about VVA symptoms
have no signs of VVA. The evaluation of sexual function and
quality of life demonstrates that VVA is associated with impaired
sexual function in postmenopausal women. The early recogni-
tion of VVA in midlife medical practice should be promoted in
Spain to allow the exclusion of other reasons for VVA-related
symptoms and to effectively treat women before the appear-
ance of advanced VVA signs with its associated complications.
This approach may beneﬁt the sexual aspects of quality of life in
women and their partners by enhancing sexual health.ACKNOWLEDGMENTS
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